TCON Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 5.27%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

TRACON Pharmaceuticals Insider Trading History Chart

TRACON Pharmaceuticals Share Price & Price History

^$0.03

▼ -0.0113 (-25.98%)

As of 12/2/2024 04:02 PM ET

TRACON Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/26/2023	Charles Theuer	CEO	Buy	199	$13.20	$2,626.80	17,620
3/9/2023	Opaleye Management Inc.	Major Shareholder	Buy	8,725	$27.60	$240,810.00	216,225
2/28/2023	Charles Theuer	CEO	Buy	10	$30.40	$304.00	17,005
1/18/2023	Charles Theuer	CEO	Buy	340	$32.40	$11,016.00	16,995
12/14/2022	Charles Theuer	CEO	Buy	1,150	$25.80	$29,670.00	16,655
12/14/2022	Opaleye Management Inc.	Major Shareholder	Buy	8,375	$25.00	$209,375.00	207,500
12/6/2022	Opaleye Management Inc.	Major Shareholder	Sell	76	$28.80	$2,188.80	200,500
11/18/2022	Charles Theuer	CEO	Buy	695	$28.20	$19,599.00	15,505
11/2/2022	Charles Theuer	CEO	Buy	300	$31.80	$9,540.00	14,350
10/18/2022	Opaleye Management Inc.	Major Shareholder	Buy	625	$33.00	$20,625.00	206,250
10/7/2022	Charles Theuer	CEO	Buy	250	$35.40	$8,850.00	13,875
10/3/2022	Charles Theuer	CEO	Buy	250	$33.40	$8,350.00	13,625
9/29/2022	Opaleye Management Inc.	Major Shareholder	Buy	470	$34.80	$16,356.00	20,500
9/27/2022	Opaleye Management Inc.	Major Shareholder	Buy	85	$33.80	$2,873.00	20,030
9/22/2022	Charles Theuer	CEO	Buy	250	$35.20	$8,800.00	13,375
9/22/2022	Opaleye Management Inc.	Major Shareholder	Buy	865	$34.60	$29,929.00	189,000
9/19/2022	Opaleye Management Inc.	Major Shareholder	Buy	250	$37.40	$9,350.00	18,750
9/12/2022	Scott B Brown	CFO	Buy	125	$40.40	$5,050.00	731
7/26/2022	Opaleye Management Inc.	Major Shareholder	Buy	112	$34.40	$3,852.80	18,500
7/22/2022	Charles Theuer	CEO	Buy	225	$37.00	$8,325.00	13,125
7/14/2022	Opaleye Management Inc.	Major Shareholder	Buy	359	$36.20	$12,995.80	17,796
7/12/2022	Charles Theuer	CEO	Buy	150	$37.40	$5,610.00	12,750
6/24/2022	Opaleye Management Inc.	Major Shareholder	Buy	570	$27.80	$15,846.00	17,436
6/21/2022	Opaleye Management Inc.	Major Shareholder	Buy	42,099	$26.20	$1,102,993.80	188,829
5/10/2022	Opaleye Management Inc.	Major Shareholder	Buy	485	$35.20	$17,072.00	146,730
5/9/2022	Charles Theuer	CEO	Buy	500	$37.00	$18,500.00	12,600
5/6/2022	Charles Theuer	CEO	Buy	125	$39.40	$4,925.00	12,100
4/29/2022	Charles Theuer	CEO	Buy	250	$39.40	$9,850.00	11,975
4/25/2022	Opaleye Management Inc.	Major Shareholder	Buy	538	$43.60	$23,456.80	146,000
4/22/2022	Opaleye Management Inc.	Major Shareholder	Buy	2,100	$44.80	$94,080.00	145,500
4/21/2022	Charles Theuer	CEO	Buy	225	$46.00	$10,350.00	11,725
4/13/2022	Opaleye Management Inc.	Major Shareholder	Buy	367	$50.00	$18,350.00	143,114
4/11/2022	Opaleye Management Inc.	Major Shareholder	Buy	455	$48.40	$22,022.00	142,209
4/8/2022	Charles Theuer	CEO	Buy	100	$50.00	$5,000.00	11,325

See Full Table

SEC Filings (Institutional Ownership Changes) for TRACON Pharmaceuticals (NASDAQ:TCON)

11.61% of TRACON Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

TRACON Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/10/2023	Opaleye Management Inc.	4,590,000	$6.84M	2.4%	+9.5%	21.429%
11/14/2022	Boothbay Fund Management LLC	258,844	$0.43M	0.0%	-3.5%	1.208%
8/16/2022	CSS LLC IL	25,119	$50K	0.0%	-70.8%	0.117%
8/15/2022	Opaleye Management Inc.	4,125,322	$8.25M	3.7%	+30.8%	20.370%
8/12/2022	Ikarian Capital LLC	2,788,853	$5.58M	1.0%	-1.9%	13.771%
2/14/2022	Opaleye Management Inc.	3,055,000	$8.46M	1.8%	+21.3%	15.710%
2/10/2022	Acadian Asset Management LLC	20,523	$55K	0.0%	+45.8%	0.106%
2/10/2022	Dowling & Yahnke LLC	47,455	$0.13M	0.0%	+17.3%	0.244%
1/18/2022	Cutler Group LP	16,200	$44K	0.0%	+1,250.0%	0.083%
12/6/2021	Psagot Value Holdings Ltd.	143,591	$0.56M	0.1%	N/A	0.738%
11/17/2021	Altium Capital Management LP	785,341	$3.04M	0.7%	N/A	4.039%
11/16/2021	Psagot Value Holdings Ltd.	143,591	$0.56M	0.1%	N/A	0.738%
11/16/2021	Two Sigma Advisers LP	367,800	$1.42M	0.0%	+29.5%	1.891%
11/16/2021	Two Sigma Investments LP	319,775	$1.24M	0.0%	+27.9%	1.644%
11/16/2021	Telemetry Investments L.L.C.	130,500	$0.51M	0.7%	+226.3%	0.671%
11/15/2021	Franklin Resources Inc.	43,700	$0.17M	0.0%	N/A	0.225%
11/15/2021	GSA Capital Partners LLP	85,993	$0.33M	0.0%	+136.4%	0.442%
11/12/2021	Renaissance Technologies LLC	306,976	$1.19M	0.0%	+76.9%	1.579%
11/12/2021	Johnson & Johnson	84,003	$0.33M	0.0%	N/A	0.432%
11/9/2021	BlackRock Inc.	299,283	$1.16M	0.0%	+1.7%	1.539%
8/25/2021	Marshall Wace LLP	56,351	$0.37M	0.0%	-60.1%	0.290%
8/17/2021	Price T Rowe Associates Inc. MD	17,400	$0.11M	0.0%	-22.3%	0.090%
8/16/2021	Telemetry Investments L.L.C.	40,000	$0.26M	0.4%	N/A	0.206%
8/16/2021	State Street Corp	72,954	$0.47M	0.0%	N/A	0.375%
8/16/2021	Marshall Wace LLP	56,351	$0.37M	0.0%	-60.1%	0.290%
8/13/2021	Renaissance Technologies LLC	173,535	$1.13M	0.0%	-27.9%	1.119%
8/13/2021	Northern Trust Corp	17,337	$0.11M	0.0%	N/A	0.112%
8/13/2021	Geode Capital Management LLC	137,822	$0.89M	0.0%	+31.3%	0.889%
8/13/2021	Vanguard Group Inc.	689,038	$4.47M	0.0%	-0.6%	4.445%
8/12/2021	Dimensional Fund Advisors LP	57,335	$0.37M	0.0%	N/A	0.370%
8/12/2021	JPMorgan Chase & Co.	8,972	$58K	0.0%	+367.3%	0.058%
8/11/2021	BlackRock Inc.	294,228	$1.91M	0.0%	-9.7%	1.898%
8/5/2021	GSA Capital Partners LLP	36,370	$0.24M	0.0%	+41.8%	0.235%
7/31/2021	Vigilare Wealth Management	17,000	$0.11M	0.1%	+21.4%	0.110%
5/18/2021	Millennium Management LLC	51,794	$0.43M	0.0%	-65.3%	0.334%
5/17/2021	CSS LLC IL	14,900	$0.12M	0.0%	+71.3%	0.096%
5/17/2021	Price T Rowe Associates Inc. MD	22,400	$0.18M	0.0%	+61.2%	0.144%
5/17/2021	Ameriprise Financial Inc.	88,484	$0.73M	0.0%	-10.0%	0.571%
5/13/2021	QS Investors LLC	43,700	$0.36M	0.0%	N/A	0.282%
5/13/2021	Renaissance Technologies LLC	240,600	$1.98M	0.0%	+42.3%	1.552%
5/13/2021	Bank of New York Mellon Corp	85,079	$0.70M	0.0%	+36.3%	0.549%
5/13/2021	X Square Capital LLC	20,973	$0.17M	0.1%	N/A	0.135%
5/12/2021	Geode Capital Management LLC	104,954	$0.86M	0.0%	+52.8%	0.677%
5/11/2021	Acadian Asset Management LLC	23,997	$0.20M	0.0%	N/A	0.155%
5/10/2021	GSA Capital Partners LLP	25,650	$0.21M	0.0%	-44.7%	0.165%
5/5/2021	Total Clarity Wealth Management Inc.	6,825	$56K	0.0%	N/A	0.044%
4/29/2021	We Are One Seven LLC	11,780	$96K	0.0%	-26.4%	0.076%
4/29/2021	Dowling & Yahnke LLC	40,455	$0.33M	0.0%	+32.8%	0.261%
4/28/2021	Lindbrook Capital LLC	6,500	$53K	0.0%	N/A	0.042%
2/17/2021	Jane Street Group LLC	11,041	$0.13M	0.0%	-71.5%	0.081%
2/16/2021	Price T Rowe Associates Inc. MD	13,900	$0.16M	0.0%	N/A	0.102%
2/9/2021	Wells Fargo & Company MN	7,329	$86K	0.0%	+166.1%	0.054%
2/9/2021	Bank of New York Mellon Corp	62,421	$0.73M	0.0%	N/A	0.456%

Data available starting January 2016

See Full Table

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Today's Range

Now: $0.03

$0.03

$0.05

50 Day Range

MA: $0.04

$0.02

$0.08

52 Week Range

Now: $0.03

$0.00

$14.75

Volume

23,800 shs

Average Volume

120,908 shs

Market Capitalization

$109,802.00

P/E Ratio

0.01

Dividend Yield

N/A

Beta

1.37

Who are the company insiders with the largest holdings of TRACON Pharmaceuticals?: TRACON Pharmaceuticals' top insider shareholders include:
Charles Theuer (CEO)
Learn More about top insider investors at TRACON Pharmaceuticals.